Decision analysis of treatment strategies in children with severe sickle cell disease

Journal of Pediatric Hematology/Oncology

Volumn 31, Issue 11, 2009, Pages 873-878

  O'Brien, Sarah H ^a   Hankins, Jane S ^b  

^a NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Decision analysis; Decision making; Quality of life; Sickle cell anemia; Sickle cell disease

Indexed keywords

HYDROXYUREA;

ARTICLE; BLOOD TRANSFUSION; CHILD; CHILDHOOD DISEASE; COMPARATIVE STUDY; DECISION TREE; DISEASE SEVERITY; DRUG FATALITY; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; HUMAN; IRON OVERLOAD; MEDICAL DECISION MAKING; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; SENSITIVITY ANALYSIS; SICKLE CELL ANEMIA; STEM CELL TRANSPLANTATION;

ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; BLOOD TRANSFUSION; CHILD; CHILD, PRESCHOOL; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; HYDROXYUREA; MALE; MODELS, THEORETICAL; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX; STEM CELL TRANSPLANTATION; TRANSPLANTATION, HOMOLOGOUS;

EID: 74249110516     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181b83cab     Document Type: Article

References (32)

1. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med. 1995;332:1317-1322.
2. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 2001;97:3628-3632.
3. WaltersMC, Storb R, PatienceM, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. Blood. 2000;95:1918-1924.
4. Miller ST, Wright E, Abboud M, et al. Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. J Pediatr. 2001;139:785-789.
5. Burd RS, Sonnenberg FA. Decision analysis: a basic overview for the pediatric surgeon. Semin Pediatr Surg. 2002;11: 46-54.
6. Drummond MF, Sculpher MJ, Torrance GW, et al. Methods for the Economic Evaluation of Health Care Programmes. 3rd ed. Oxford [England]; New York: Oxford University Press; 2005;147-154.
7. Mazumdar M, Heeney MM, Sox CM, et al. Preventing stroke among children with sickle cell anemia: an analysis of strategies that involve transcranial Doppler testing and chronic transfusion. Pediatrics. 2007;120:e1107-e1116.
8. Nietert PJ, Abboud MR, Silverstein MD, et al. Bone marrow transplantation versus periodic prophylactic blood transfusion in sickle cell patients at high risk of ischemic stroke: a decision analysis. Blood. 2000;95:3057-3064.
9. Scott JP, Hillery CA, Brown ER, et al. Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr. 1996;128:820-828.
10. Ferster A, Vermylen C, Cornu G, et al. Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood. 1996;88:1960-1964.
11. Hankins JS, Ware RE, Rogers ZR, et al. Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood. 2005;106:2269-2275.
12. Jayabose S, Tugal O, Sandoval C, et al. Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr. 1996;129:559-565.
13. Koren A, Segal-Kupershmit D, Zalman L, et al. Effect of hydroxyurea in sickle cell anemia: a clinical trial in children and teenagers with severe sickle cell anemia and sickle cell betathalassemia. Pediatr Hematol Oncol. 1999;16:221-232.
14. Rogers ZR. Hydroxyurea therapy for diverse pediatric populations with sickle cell disease. Semin Hematol. 1997;34: 42-47.
15. Hankins J, Jeng M, Harris S, et al. Chronic transfusion therapy for children with sickle cell disease and recurrent acute chest syndrome. J Pediatr Hematol Oncol. 2005;27:158-161.
16. Styles LA, Vichinsky E. Effects of a long-term transfusion regimen on sickle cell-related illnesses. J Pediatr. 1994;125: 909-911.
17. Leikin SL, Gallagher D, Kinney TR, et al. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics. 1989;84:500-508.
18. Prasad R, Hasan S, Castro O, et al. Long-term outcomes in patients with sickle cell disease and frequent vaso-occlusive crises. Am J Med Sci. 2003;325:107-109.
19. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. JAMA. 2003;289:1645-1651.
20. Bakanay SM, Dainer E, Clair B, et al. Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005;105:545-547.
21. Zambon M, Vincent JL. Mortality rates for patients with acute lung injury/ARDS have decreased over time. Chest. 2008;133:1120-1127.
22. Bernaudin F, Souillet G, Vannier JP, et al. Report of the French experience concerning 26 children transplanted for severe sickle cell disease. Bone Marrow Transplant. 1997; 19(suppl. 2):112-115.
23. Vermylen C, Cornu G, Ferster A, et al. Haematopoietic stem cell transplantation for sickle cell anaemia: the first 50 patients transplanted in Belgium. Bone Marrow Transplant. 1998;22: 1-6.
24. Panepinto JA, Walters MC, Carreras J, et al. Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. Br J Haematol. 2007;137:479-485.
25. Harmatz P, Butensky E, Quirolo K, et al. Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy. Blood. 2000; 96:76-79.
26. Karam LB, Disco D, Jackson SM, et al. Liver biopsy results in patients with sickle cell disease on chronic transfusions: poor correlation with ferritin levels. Pediatr blood cancer. 2008; 50:62-65.
27. Gold MR, Franks P, McCoy KI, et al. Toward consistency in cost-utility analyses: using national measures to create condition- specific values. Med Care. 1998;36:778-792.
28. Wood JC, Tyszka JM, Carson S, et al. Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease. Blood. 2004;103:1934-1936.
29. Brawley OW, Cornelius LJ, Edwards LR, et al. National institutes of health consensus development conference statement: hydroxyurea treatment for sickle cell disease. Ann Intern Med. 2008;148:932-938.
30. O'Brien SH. Decision analysis in pediatric hematology. Pediatr clin N Am. 2008;55:287-304, vii.
31. Griebsch I, Coast J, Brown J. Quality-adjusted life-years lack quality in pediatric care: a critical review of published cost-utility studies in child health. Pediatrics. 2005;115: e600-e614.
32. Panepinto JA, Pajewski NM, Foerster LM, et al. The performance of the PedsQL generic core scales in children with sickle cell disease. J Pediatr Hematol Oncol. 2008;30: 666-673.